Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | NSD2 | O96028 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.49 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.49 |
| ▸ | F12 | P00748 | 1/20 | 0.38 |
| ▸ | INSR | P06213 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | APP | P05067 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.38 |
| ▸ | SNCA | P37840 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | PMM2 | O15305 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrazine SCHEMBL654287 | 0.80 | F12 (0.55) | MAPTRAB9ANPC1ALDH1A1F12 | |
| Hydrazine SCHEMBL9146358 | 0.79 | F12 (0.53) | MAPTRAB9ANPC1ALDH1A1F12 | |
| SCHEMBL61339 | 0.77 | F12 (0.59) | MAPTRAB9ANPC1ALDH1A1F12 | |
| Hydrochloric Acid SCHEMBL1719468 | 0.75 | F12 (0.57) | MAPTRAB9ANPC1ALDH1A1F12 | |
| Formaldehyde SCHEMBL28698810 | 0.75 | F12 (0.57) | MAPTRAB9ANPC1ALDH1A1F12 | |
| Hydrochloric Acid SCHEMBL28900590 | 0.74 | F12 (0.55) | MAPTRAB9ANPC1ALDH1A1F12 | |
| SCHEMBL2768273 | 0.71 | SIGMAR1 (0.45) | MAPTCYP2A6SIGMAR1CYP19A1 | |
| SCHEMBL22740301 | 0.71 | ALDH1A1 (0.48) | MAPTRAB9ANPC1NSD2ALDH1A1 | |
| SCHEMBL5470608 | 0.71 | CYP2A6 (0.45) | MAPTRAB9AALDH1A1CYP2A6MEN1 | |
| SCHEMBL10425765 | 0.71 | ALDH1A1 (0.49) | MAPTRAB9ANPC1NSD2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2000030632-A1 | ARYL AND HETEROARYL COMPOUNDS USEFUL AS FIBROBLAST GROWTH FACTOR ANTAGONISTS | EISAI CO., LTD. (JP) | 2000-06-02 | — | — | WO | claimed |
| US-20140221455-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | Verva Pharmaceuticals, Inc. (AU) | 2014-08-07 | — | — | US | disclosed |
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | VERVA PHARMACEUTICALS PTY LTD (AU) | 2012-03-08 | — | — | US | disclosed |
| US-20050282733-A1 | Differentiation modulating agents and uses therefor | VERVA PHARMACEUTICALS PTY LTD (AU) | 2005-12-22 | — | — | US | disclosed |
| WO-2005065686-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | ADIPOGEN PHARMACEUTICALS PTY LIMITED (AU) | 2005-07-21 | — | — | WO | disclosed |
| WO-2000030632-A1 | ARYL AND HETEROARYL COMPOUNDS USEFUL AS FIBROBLAST GROWTH FACTOR ANTAGONISTS | EISAI CO., LTD. (JP) | 2000-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | FGF1, FABP4, FGF2 | MAPT 4367/4885RAB9A 2690/4885NPC1 2593/4885 |
| US-20050282733-A1 | Differentiation modulating agents and uses therefor | FGF1, FABP4, FGF2 | MAPT 4367/4885RAB9A 2690/4885NPC1 2593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.